The nation of Zimbabwe has declined a substantial American health deal worth $367m (£272m) over five years over Washington's demand for confidential information.
This rejection came to light following a government memo from December was disclosed, which showed President Emmerson Mnangagwa deemed the arrangement was "skewed".
An official spokesman later stated that the US was seeking biological samples for research and profit while was unwilling to share the resulting advantages from future medical innovations.
"We must now begin the challenging and unfortunate task of ending our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the United States had furnished over $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for more dialogue to reach a agreement suitable to both sides so the nation's vital HIV programme can continue.
Broader Background
This rejection comes after a similar case in Kenya, where a high court halted a similar health funding agreement after concerns were raised about the safety of Kenyans' medical information.
After returning to the presidency last year, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
USAID had overseen aid for the American government, but Trump argued its spending was "inefficient" and his government was seeking government-to-government agreements to boost transparency and accountability.
As per statements, Sixteen African countries have so far signed similar health pacts, constituting more than $18.3bn of fresh investment.
Details of the Rejected Agreement
The money for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this partnership would have delivered immense advantages for the people of Zimbabwe, especially the 1.2 million presently on antiretroviral therapy through US-supported programmes," Tremont commented.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"Zimbabwe was being asked to provide its biological resources and data for a long time, with no equivalent promise of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might result from that shared data," Mangwana explained.
"In essence, our country would provide the basic resources for medical research with no assurance that the resulting innovations would be accessible to our population if a new disease outbreak arise."
Sovereignty and Global Health
He also noted that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were undermining systems already set up through the global organization.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme created to manage potential global health emergencies.
"This framework is intended to guarantee that when a country provides its information, the resulting advantages – including vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the capability to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We welcome ongoing dialogue with our US partners on how future collaboration might be arranged in a way that honours the independence and dignity of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it understood the government's concerns, but urged that negotiations should continue given that a large portion of the nation's HIV programmes depended on foreign aid.
"If technical issues exist, such as those involving data governance or implementation frameworks, these can often be addressed through detailed discussion and mutually agreed protections," the group commented.
This impasse underscores the continuing tensions between receiving vital foreign assistance and protecting local interests in an increasingly data-driven world.